Inactive Instrument

Analyst Reco. VectivBio Holding AG

Equities

Credit Suisse Downgrades VectivBio Holding to Neutral From Outperform on Heels of Announced Sale to Ironwood Pharmaceuticals, Lowers PT to $17 From $22	23-05-23	MT
Piper Sandler Downgrades VectivBio to Neutral From Overweight, Adjusts Price Target to $17 From $25	23-05-23	MT
SVB Securities Downgrades VectivBio to Market Perform From Outperform, Adjusts Price Target to $17 From $30	23-05-23	MT
Piper Sandler Adjusts VectivBio Price Target to $25 From $23, Maintains Overweight Rating	23-04-20	MT
Jefferies Starts VectivBio Holding at Buy With $18 Price Target	22-12-13	MT
Piper Sandler Starts VectivBio at Overweight With $23 Price Target	22-07-01	MT
Credit Suisse Lowers VectivBio Holding's Price Target to $19 from $24, Maintains Outperform Rating	22-02-14	MT
VECTIVBIO : Credit Suisse Starts VectivBio Holding at Outperform with $24 Price Target	21-05-04	MT
VECTIVBIO : BofA Securities Initiates Coverage on VectivBio With Buy Rating, $19 Price Target	21-05-04	MT
VECTIVBIO : SVB Leerink Initiates Coverage on VectivBio With Outperform Rating, $28 Price Target	21-05-04	MT

No results for this search